The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 20.50
Bid: 20.00
Ask: 21.00
Change: -0.25 (-1.20%)
Spread: 1.00 (5.00%)
Open: 20.75
High: 20.75
Low: 20.50
Prev. Close: 20.75
IOF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

6 Feb 2023 07:00

RNS Number : 9459O
Iofina PLC
06 February 2023
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF REGULATION (EU) NO 596/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 16 APRIL 2014 ON MARKET ABUSE (MARKET ABUSE REGULATION) AS RETAINED AS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 AS AMENDED.

 

6 February 2023

 

Iofina Plc

("Iofina" or the "Company")

(AIM: IOF)

 

 Trading Update

FY 2022 EBITDA expected to exceed market expectations

 

Iofina plc, specialists in the exploration and production of iodine and manufacturers of specialty chemical products, provides the following trading update.

 

Subject to the completion of the Company's full year audited results, which are expected to be released in May 2023, Iofina is pleased to report that it now expects its FY 2022 EBITDA1 to be materially ahead of the previous market forecast and no less than $10.5 million. Revenues for FY 2022 remain in line with current guidance.

 

As noted in the Company's previous update on 11 January 2023, global demand for both iodine and iodine-based derivatives were strong throughout 2022, with prices rising during H1 2022 and remaining high in H2 2022. As a result, sales margins achieved by Iofina in H2 2022 were robust and combined with our improved iodine production, the Company delivered stronger second half profitability than previously anticipated. 

 

The Company also confirms that the construction of its newest IOsorb® plant, IO#9, continues to progress within the expected timelines. Dirt work, concrete, tanks placement and building structures are well underway. Additionally, the items that will be repurposed from IO#5 have been dismantled for use at IO#9. Business development opportunities for future iodine production sites continue to progress positively.

 

The Company notes that iodine prices have remained steady into Q1 2023 and it continues to see robust demand for its iodine and iodine derivatives.

 

Commenting, President and CEO of Iofina Dr. Tom Becker, stated: "2022 was a year of significant progress for Iofina. Solid iodine production performance, higher prices and strong demand for iodine, and the beginning of construction of our newest plant IO#9 are all examples of the positive momentum that the Company is carrying forward into 2023. The Board now expects 2022 EBITDA to exceed market estimates and we look forward to releasing the Company's fully audited 2022 results in May. We are excited for the commencement of production at our IO#9 plant later in Q2 2023 which is anticipated to produce 100-150MT of crystalline iodine per annum."

 

 

1 EBITDA is a non-IFRS measure and refers to Earnings Before Interest, Tax, Depreciation and Amortisation.

 

Enquiries:

 

Dr. Tom Becker

CEO & President

Iofina plc

Tel: +44 (0)20 3006 3135

 

Nomad & Broker:

Henry Fitzgerald-O'Connor/Patrick Dolaghan/Andrew Potts

Canaccord Genuity Limited

Tel: +44 (0)20 7523 8000

 

Financial Adviser:

Kingsley Wilson

Chrystal Capital Partners LLP

Tel: +44 (0)20 7850 4761

 

Media Contact:

Charles Goodwin/Shivantha Thambirajah/Jazmine Clemens

Yellow Jersey PR Limited

Tel: +44 (0)7747 788 221/+44 (0)7983 521 488

About Iofina:

Iofina plc (AIM: IOF) is a vertically integrated company that specialises in the production of Iodine and the manufacturing of specialty chemical products. Iofina is the second largest producer of iodine in North America and operates the manufacturing entities Iofina Resources and Iofina Chemical.

 

LEI: 213800QDMFYVRJYYTQ84

ISIN: GB00B2QL5C79

 

Iofina Resources

Iofina Resources develops, builds, owns and operates iodine extraction plants using Iofina's WET® IOsorb® technology. Iofina currently operates five producing IOsorb® plants in Oklahoma and is consistently using technology and innovation to improve and expand its operations.

 

Iofina Chemical

Iofina Chemical has manufactured high quality halogen speciality chemicals derived from raw iodine, as well as non-iodine based products. Iofina Chemical will be celebrating its 40th anniversary in 2023 as a preeminent halogen-based specialty chemicals company.

 

www.iofina.com

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTVELFBXLLXBBQ
Date   Source Headline
26th Aug 20207:00 amRNSDebt Update
31st Jul 20208:00 amRNSLaunch of new website
22nd Jul 202011:06 amRNSSecond Price Monitoring Extn
22nd Jul 202011:00 amRNSPrice Monitoring Extension
22nd Jul 20207:00 amRNSCorporate Update
30th Jun 20202:36 pmRNSDebt Update
30th Jun 202011:52 amRNSResult of AGM
26th Jun 20201:26 pmRNSChange of venue for AGM on 30 June 2020
26th Jun 20207:00 amRNSIO#8 and Debt Update
27th May 20207:00 amRNSFinal Results
19th May 20204:41 pmRNSSecond Price Monitoring Extn
19th May 20204:36 pmRNSPrice Monitoring Extension
15th May 20204:40 pmRNSSecond Price Monitoring Extn
15th May 20204:35 pmRNSPrice Monitoring Extension
14th May 20207:00 amRNSPPP Loan Received
4th May 20207:00 amRNSIO#8 Brine Supply Update
14th Apr 20207:00 amRNSQ1 Market Update
2nd Apr 20207:00 amRNSDirectorate Change
26th Mar 20201:53 pmRNSWithdrawal of requisition for General Meeting
19th Mar 202012:08 pmRNSSecond Price Monitoring Extn
19th Mar 202012:03 pmRNSPrice Monitoring Extension
17th Mar 20204:41 pmRNSSecond Price Monitoring Extn
17th Mar 20204:35 pmRNSPrice Monitoring Extension
16th Mar 202012:07 pmRNSSecond Price Monitoring Extn
16th Mar 202012:02 pmRNSPrice Monitoring Extension
12th Mar 20204:41 pmRNSSecond Price Monitoring Extn
12th Mar 20204:36 pmRNSPrice Monitoring Extension
12th Mar 20201:56 pmRNSClarification Regarding Media Reports
11th Mar 202012:08 pmRNSSecond Price Monitoring Extn
11th Mar 202012:02 pmRNSPrice Monitoring Extension
10th Mar 20207:30 amRNSBoard response to recent GM request
10th Mar 20207:00 amRNSRequisition of General Meeting
3rd Mar 20207:10 amRNSStatement re: press and social media reports
2nd Mar 202012:22 pmRNSHolding(s) in Company
25th Feb 202012:00 pmRNSMarket Update
10th Feb 20205:15 pmRNSHolding(s) in Company
10th Feb 20205:15 pmRNSHolding(s) in Company
16th Jan 20207:00 amRNSMarket Update - Strong H2 2019
2nd Jan 202011:11 amRNSHolding(s) in Company
20th Dec 20197:00 amRNSTrading Update
14th Nov 20193:51 pmRNSHolding(s) in Company
14th Nov 20193:50 pmRNSHolding(s) in Company
12th Nov 20191:43 pmRNSHolding(s) in Company
6th Nov 20197:00 amRNSIofinaEX Hemp Seed Investment
14th Oct 20197:00 amRNSQ3 2019 Update
26th Sep 201910:00 amRNSHolding(s) in Company
25th Sep 20194:35 pmRNSPrice Monitoring Extension
23rd Sep 20197:00 amRNSInterim Results
18th Sep 20197:00 amRNSTerms for IO#8 Finalised - Construction Commences
29th Aug 20194:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.